Why the study?
A unified definition and classification of renal injury remain necessary, and categorizing multifactorial renal insufficiency into monogenous phenotypes is difficult in heart failure.
This review highlights the prognostic importance of renal insufficiency in heart failure and summarizes the renal effects and therapeutic considerations of key heart failure medications.
Renal monitoring guides HF therapy decisions; review extends cardiorenal evidence on RAASi/ARNI/SGLT2i yet leaves optimal strategies open.
The heart and kidneys are closely related vital organs that significantly affect each other. Cardiorenal syndrome is the term depicting the various spectra of cardiorenal interaction mediated by the hemodynamic, neurohormonal, and biochemical cross-talk between these two organs. In patients with heart failure (HF), both the baseline and worsening renal function are closely related to prognosis. However, for both investigational and clinical purposes, the unified definition and classification of renal injury are still necessary. Renal insufficiency is caused by multiple factors, and categorizing them into monogenous subgroups of phenotype is difficult. Various clinical scenarios related to the chronicity of HF, progression of renal dysfunction, and issues related to pharmacologic therapies associated with the prognosis of patients with HF have been reviewed in this study.
No takes yet. Share an insight, caveat, or question.
Jang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: